Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experience
نویسندگان
چکیده
BACKGROUND Chemoradiotherapy for head and neck cancer (SCCHN) is challenging in elderly, multi-morbid patients. Radioimmunotherapy (RIT) with cetuximab provides an option to enhance efficacy of radiotherapy without increased toxicity. We present a single-centre experience of RIT these patients. METHODS Toxicity and outcome was retrospectively analysed in patients treated with radiotherapy and cetuximab between 2006 and 2009. Treatment response was analysed at first follow-up, outcome was estimated using Kaplan-Meier analyses. RESULTS 73 patients with primary/recurrent SCCHN were treated (re-irradiation: 22 patients). CTC grade 3 allergic reactions occurred in 4 patients, grade 3 acneiforme skin reactions leading to discontinuation of cetuximab in 3 patients.Overall response rate was 59,4%, median locoregional and overall progression-free survival (PFS) was 18 and 15 months, overall survival (OS) 18 months. CONCLUSION RIT is a feasible treatment option for elderly and multi-morbid patients with promising therapeutic activity. Long-term disease control can also be achieved in patients receiving RIT for re-irradiation.
منابع مشابه
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial.
BACKGROUND The purpose of this study was to assess the efficacy, safety, and pharmacokinetics of cisplatin-based chemotherapy plus cetuximab as first-line treatment in Chinese and Korean patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). METHODS Patients (n = 68) received cetuximab weekly plus 3-week cycles of cisplatin/5-fluorouracil (5-FU) chemot...
متن کاملPrognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy
Despite modern treatment approaches, survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) remains low and it is difficult to identify patients who derive optimal benefit from treatment. We therefore analyzed which commonly available laboratory and clinical parameters may help improve the prognostication in this patient group. This retrospective ...
متن کاملTreatment of Locally Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck
The survival rate at 3 years after potentially curative surgical or radiation treatment for locally advanced squamous cell carcinoma of head and neck (SCCHN) remains quite poor at 30 to 50%. Over 50% of these patients relapse locally or at distant sites and with a median survival of 6-9 months. This review focuses on the established and experimental strategies seeking to improve this outcome. C...
متن کاملRhabdomyosarcoma: Nose Presenting As Second Primary with Carcinoma Tongue
Introduction Presence of two primary malignancies is rare and occurs in 3-5% of the cancer patients. As per our extensive internet research, this is the only reported case of a synchronous sino-nasal embryonal rhabdomyosarcoma with squamous cell carcinoma-tongue. The case report is important because of the rare diagnosis and the challenge we faced in the diagnosis and treatment of the pat...
متن کاملInitial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
In Japan, cetuximab with concurrent bioradiotherapy (BRT) for squamous cell carcinoma of head and neck (SCCHN) was approved in December 2012. We herein report our initial experience of BRT, with special emphasis on acute toxicities of this combination therapy. Thirty-one non-metastatic SCCHN patients who underwent BRT using cetuximab between July 2013 and June 2014 were retrospectively evaluate...
متن کامل